Heron Therapeutics (LTS:0J4V) FCF Margin %: -5.56% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0J4V Heron Therapeutics Inc LTS:0J4V
50 GF Score
Price $0.48
GF Value $1.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics FCF Margin %?

Heron Therapeutics LTS:0J4V +15.28% 50 FCF Margin % is -5.56% as of Mar. 2026. GuruFocus rates LTS:0J4V with a GF Score™ of 50/100 and a GF Value™ of $1.55 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 950 Biotechnology companies, Heron Therapeutics ranks better than 66.21% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Heron Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-1.9 Mil. Heron Therapeutics's Revenue for the three months ended in Mar. 2026 was $34.7 Mil. Therefore, Heron Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -5.56%.

As of today, Heron Therapeutics's current FCF Yield % is -23.01%.

The historical rank and industry rank for Heron Therapeutics's FCF Margin % or its related term are showing as below:

LTS:0J4V' s FCF Margin % Range Over the Past 10 Years
Min: -10729.63   Med: -177.17   Max: -13.84
Current: -13.84

During the past 13 years, the highest FCF Margin % of Heron Therapeutics was -13.84%. The lowest was -10729.63%. And the median was -177.17%.

LTS:0J4V's FCF Margin % is ranked better than
66.21% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs LTS:0J4V: -13.84

Heron Therapeutics FCF Margin % Related Terms

Heron Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics FCF Margin % Chart

Heron Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -239.01 -138.14 -47.49 -16.80 -18.02

Heron Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.08 -29.77 3.48 -22.63 -5.56

LTS:0J4V vs ENTX, OKYO, EDSA: FCF Margin % Comparison

For the Biotechnology subindustry, Heron Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heron Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's FCF Margin % falls into.


LTS:0J4V
50GF Score
Heron Therapeutics Inc LTS:0J4V
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Heron Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-27.908/154.904
=-18.02 %

Heron Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.931/34.711
=-5.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -5.56% mean?
Heron Therapeutics (LTS:0J4V) has a FCF Margin % of -5.56% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Heron Therapeutics and its competitors. According to the industry distribution chart, Heron Therapeutics ranks #321 out of 950 companies in the Biotechnology industry, placing it in the top 33.8%.
Is Heron Therapeutics' FCF Margin % too high?
Heron Therapeutics' current FCF Margin % is -5.56%. Based on the distribution chart, Heron Therapeutics ranks #321 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Heron Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' FCF Margin % compare to ENTX and OKYO?
According to the Biotechnology industry distribution chart, Heron Therapeutics ranks #321 out of 950 companies for FCF Margin %. This puts Heron Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current FCF Margin % is -5.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (LTS:0J4V) is currently considered Possible Value Trap. The stock's GF Value™ is $1.55, compared to a current price of $0.48 — trading 68.8% below its estimated fair value. The current FCF Margin % is -5.56%. Heron Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Heron Therapeutics (LTS:0J4V), the current FCF Margin % is -5.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (LTS:0J4V) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of $0.48 is trading 68.8% below its estimated GF Value™ of $1.55. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0J4V:

  • FCF Margin %: -5.56%
  • GF Value™: $1.55 vs. price of $0.48 (68.8% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the LTS:0J4V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USAAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
50GF Score

Get the complete analysis for LTS:0J4V

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$1.55
GF Value